Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis
- 1 March 2004
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 65 (3), 757-767
- https://doi.org/10.1111/j.1523-1755.2004.00450.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Biological basis of anemiaSeminars in Oncology, 2001
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997
- Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patientsAmerican Journal of Kidney Diseases, 1995
- Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysisAustralian and New Zealand Journal of Medicine, 1991
- Low-Dose Recombinant Human Erythropoietin Therapy in Chronic Hemodialysis PatientsAmerican Journal of Kidney Diseases, 1991
- Treatment of Transfusion-Dependent Anaemia of Chronic Renal Failure with Recombinant Human Erythropoietin: A European multicentre study in 142 patients to define dose regimen and safety profileNephrology Dialysis Transplantation, 1991
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- The Sickness Impact Profile: Development and Final Revision of a Health Status MeasureMedical Care, 1981